NCT06563869View on ClinicalTrials.gov

Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma

PHASE3RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 2, 2024

Primary Completion Date

November 22, 2025

Study Completion Date

November 22, 2026

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

PEG-rhG-GSF

Polyethylene glycolylated recombinant human granulocyte stimulating factor （6mg）will be given 24 hours after the end of chemotherapy.

Trial Locations (1)

210029

RECRUITING

the First Affiliated Hospital of Nanjing Medical University, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER